Supporting Access & Commercialisation in Rare Diseases
ENTRI Access2Rare empowers rare disease biotech and pharmaceutical companies to successfully navigate market access and launch therapies across Europe’s mid-sized markets. With deep expertise in regulatory strategy, payer engagement, HTA navigation, launch readiness, commercialisation and digital engagement, combined with local knowledge across 31 European markets, we help ensure your orphan drug reaches the patients who need it - efficiently and compliantly. We support clients across Europe with tailored solutions spanning early access, reimbursement, launch and market implementation.
From Rare Disease Therapy to Patient Access
ENTRI is driven by a singular purpose: to assist companies in achieving successful reimbursement and seamless product launches in select countries across Europe. With our in-depth knowledge of the healthcare landscape in the region, we specialize in navigating complex reimbursement systems and overcoming market access barriers.
What sets us apart is our unrivaled expertise in negotiating access for rare therapies. Our team of seasoned commercialization experts possesses a deep understanding of the unique challenges faced by companies in this space. We leverage this knowledge to craft tailored strategies and provide invaluable support throughout the entire product lifecycle.
Partnering with ENTRI means working with a team dedicated to your success. We are committed to delivering exceptional results, helping you overcome hurdles, and ensuring your breakthrough therapies reach the patients who need them most. With our comprehensive approach and unwavering focus on excellence, we are your trusted ally in the journey towards improved patient outcomes.
Together, let's redefine the landscape of healthcare access, create meaningful change, and make a lasting impact in the lives of patients across Europe!
Flexible Resourcing for Lean Teams
Bridge internal resource and expertise gaps with senior external support.
Commercializing a product in Europe requires resources many biotech teams don’t have in-house. ENTRI provides flexible, senior-level support for market access, pricing, and launch execution - when internal capacity is limited or stretched.
Local Market Access Expertise Across Europe
Navigate country-specific reimbursement with confidence.
Each EU country has its own HTA system, pricing pathway and stakeholder expectations. ENTRI brings deep local insight, native-language skills and experience engaging with key experts and patient advocacy groups (PAGs) to help you shape and execute successful access strategies tailored to each market.
End-to-End Rare Disease Launch Experience
ENTRI combines strategic insight with practical experience across European rare disease launches. From early planning and payer negotiations to commercialisation and digital engagement, we support your team with proven methods, tailored digital solutions and actionable plans that turn strategy into effective market execution.
Scalable Support for Shifting Priorities
Stay agile as timelines, pipelines and business needs change.
Biotech companies face constant change - shifting timelines, evolving pipelines, and unexpected challenges. ENTRI helps you stay on track by taking ownership of specific market access or launch activities, so you can focus on what’s next.
Local expertise across 31 European markets
ENTRI Access2Rare brings together experienced external partners with local knowledge across 31 European markets - home to more than 212 million people.
Our footprint extends across the Nordics, Benelux, Ireland, Switzerland, Austria, Central and Eastern Europe, Greece, Cyprus and Malta. These markets may be smaller individually, but together they represent a significant part of Europe and an important opportunity for companies developing innovative rare disease treatments.
Every market has its own healthcare structures, decision-making processes and stakeholder environment. Our broad geographical coverage combines strong in-country understanding with a connected European perspective.
Markets covered by ENTRI Access2Rare
Nordics: Denmark, Finland, Iceland, Norway and Sweden
Benelux: Belgium, Luxembourg and the Netherlands
Other European markets: Austria, Ireland and Switzerland
Central and Eastern Europe: Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Estonia, Hungary, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia and Slovenia
Mediterranean markets: Cyprus, Greece and Malta
Our services are designed to help you successfully launch in Europe
ENTRI has extensive experience in commercializing orphan drugs across the European mid-size markets. We build the optimal launch strategy across the region, by country and successfully manage the execution. We combine our team setup based on your unique needs; ensuring a targeted and cost-efficient approach.
Unlock Rare Disease Solutions
Partner with ENTRI Access2Rare for expert consultancy that simplifies market entry and accelerates patient access to rare disease treatments in Europe.